We are live on ! Find out more
BCM

BIOS Capital Management Portfolio holdings

AUM $52.9M
1-Year Est. Return 30.51%
This Fund
S&P 500
This Quarter Est. Return
+5.74%
1 Year Est. Return
+30.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$94.1M
AUM Growth
–
Cap. Flow
+$96.6M
Cap. Flow %
102.67%
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ACTU
Actuate Therapeutics
ACTU
+$80.7M
2
RNTX
Rein Therapeutics
RNTX
+$5.12M
3
LTRN icon
Lantern Pharma
LTRN
+$4.14M
4
CGTX icon
Cognition Therapeutics
CGTX
+$2.97M
5
INAB icon
IN8bio
INAB
+$2.52M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACTU
1
Actuate Therapeutics
ACTU
$26.6M
$78.8M 83.69%
+9,893,651
New +$80.7M
CGTX icon
2
Cognition Therapeutics
CGTX
$79.6M
$4.21M 4.47%
+6,000,000
New +$2.97M
RNTX
3
Rein Therapeutics
RNTX
$63.1M
$3.89M 4.13%
+1,690,751
New +$5.12M
LTRN icon
4
Lantern Pharma
LTRN
$33.6M
$3.85M 4.09%
+1,207,709
New +$4.14M
INAB icon
5
IN8bio
INAB
$9.88M
$2.21M 2.35%
+286,667
New +$2.52M
IRD
6
Opus Genetics
IRD
$306M
$1.18M 1.26%
+995,249
New +$1.14M

Similar funds

FRGX
First Reserve GP XIII Stamford, Connecticut $52.9M AUM 17.37% 1-Year Est. Return
ICM
Irth Capital Management New York $52.8M AUM 21.11% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
GMEI
Global Media & Entertainment Investments Nassau, Bahamas $53M AUM 0% 1-Year Est. Return
TP
Toronado Partners San Francisco, California $53M AUM 13.38% 1-Year Est. Return
ETCM
Evolutionary Tree Capital Management Alexandria, Virginia $53.2M AUM 13.56% 1-Year Est. Return
WEO
William E. Oberndorf $53.3M AUM 10.89% 1-Year Est. Return
NCM
Notable Capital Management Menlo Park, California $53.4M AUM 10.98% 1-Year Est. Return

BIOS Capital Management's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for BIOS Capital Management, which disclosed 6 positions worth $94.1M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Actuate Therapeutics: 9,893,651 shares worth $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • BIOS Capital Management's largest Q4 2024 buy was Actuate Therapeutics: 9,893,651 shares worth $78.8M.
  • BIOS Capital Management's ten largest holdings make up 100% of its $94.1M portfolio in Q4 2024.
  • BIOS Capital Management disclosed 6 positions in Q4 2024, its first 13F filing on record.

Based on BIOS Capital Management's 13F filing for Q4 2024, filed 10 Feb 2025.